
<table style="border-collapse:collapse;" class=table-fill border=1>
<thead>
<tr>
  <th id="tableHTML_header_1">Group</th>
  <th id="tableHTML_header_2">Interventions</th>
  <th id="tableHTML_header_3">Descriptions/mechanisms of action</th>
  <th id="tableHTML_header_4">text</th>
  <th id="tableHTML_header_5">More information</th>
</tr>
</thead>
<tbody>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">acetyl-L-carnitine</td>
  <td id="tableHTML_column_3">acetyl-L-carnitine acetylated form of the amino acid derivative L-carnitine, which aids mitochondrial fatty acid metabolism.</td>
  <td id="tableHTML_column_4">acetyl-L-carnitine is a <u>Nutraceutical</u> intervention. <br>acetyl-L-carnitine acetyl-L-carnitine acetylated form of the amino acid derivative L-carnitine, which aids mitochondrial fatty acid metabolism.. The use of acetyl-L-carnitine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">alpha-lipoic acid</td>
  <td id="tableHTML_column_3">alpha-lipoic acid antioxidant with insulin-mimetic and anti-inflammatory activity</td>
  <td id="tableHTML_column_4">alpha-lipoic acid is a <u>Nutraceutical</u> intervention. <br>alpha-lipoic acid alpha-lipoic acid antioxidant with insulin-mimetic and anti-inflammatory activity. The use of alpha-lipoic acid in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">acetylsalicylic acid</td>
  <td id="tableHTML_column_3">acetylsalicylic acid anti-inflammatory, platelet aggregation inhibitor</td>
  <td id="tableHTML_column_4">acetylsalicylic acid is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is acetylsalicylic acid anti-inflammatory, platelet aggregation inhibitor. The use of acetylsalicylic acid in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">agomelatin</td>
  <td id="tableHTML_column_3">agomelatin melatonin, serotonin receptor agonist (Mel1,Mel2), receptor antagonist (5-HT2B, 5-HT2C)</td>
  <td id="tableHTML_column_4">agomelatin is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is agomelatin melatonin, serotonin receptor agonist (Mel1,Mel2), receptor antagonist (5-HT2B, 5-HT2C). The use of agomelatin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">allopurinol</td>
  <td id="tableHTML_column_3">allopurinol xanthine oxidase inhibitor</td>
  <td id="tableHTML_column_4">allopurinol is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is allopurinol xanthine oxidase inhibitor. The use of allopurinol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">amitriptyline</td>
  <td id="tableHTML_column_3">amitriptyline norepinephrine, serotonin reuptake inhibitor, receptor antagonist (5-HT2)</td>
  <td id="tableHTML_column_4">amitriptyline is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is amitriptyline norepinephrine, serotonin reuptake inhibitor, receptor antagonist (5-HT2). The use of amitriptyline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">aripiprazole</td>
  <td id="tableHTML_column_3">aripiprazole dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A)</td>
  <td id="tableHTML_column_4">aripiprazole is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is aripiprazole dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A). <br><u>This intervention is indicated in</u> <ul><li> Bipolar disorder type I -Acute treatment of manic and mixed episodes with a recommeded dose of 15 mg/day with a recommeded dose of 15 mg/day up to a maximum dose of 30 mg/day up to a maximum dose of 30 mg/day </li><li> Agitation associated with bipolar mania up to a maximum dose of 30 mg/day injected IM up to a maximum dose of 30 mg/day injected IM </li><li> Bipolar I disorder  - acute  treatment of manic and mixed  episodes) - pediatric patients (age  10-17) with a recommeded dose of 10 mg/day with a recommeded dose of 10 mg/day up to a maximum dose of 30 mg/day up to a maximum dose of 30 mg/day </li><li> Maintenance treatment of bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate with a recommeded dose of The recommended dose for maintenance treatment is the same dose needed to stabilize patients during acute treatment, both for adult and pediatric patient. with a recommeded dose of The recommended dose for maintenance treatment is the same dose needed to stabilize patients during acute treatment, both for adult and pediatric patient.</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">armodafinil</td>
  <td id="tableHTML_column_3">armodafinil dopamine reuptake inhibitor (DAT)</td>
  <td id="tableHTML_column_4">armodafinil is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is armodafinil dopamine reuptake inhibitor (DAT). The use of armodafinil in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">asenapine</td>
  <td id="tableHTML_column_3">asenapine dopamine, serotonin, norepinephrine receptor antagonist (5-HT2, D2, NE alpha-2)</td>
  <td id="tableHTML_column_4">asenapine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is asenapine dopamine, serotonin, norepinephrine receptor antagonist (5-HT2, D2, NE alpha-2). <br><u>This intervention is indicated in</u> <ul><li> Bipolar mania-adults: acute and maintenance monotherapy with a recommeded dose of 5-10 mg sublingually twice daily with a recommeded dose of 5-10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily </li><li> Bipolar mania – pediatric patients (10 to 17 years): monotherapy with a recommeded dose of 2.5-10 mg sublingually twice daily with a recommeded dose of 2.5-10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily </li><li> Bipolar mania – adults: as an adjunct to lithium or valproate with a recommeded dose of 5-10 mg sublingually twice daily with a recommeded dose of 5-10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">brexpiprazole</td>
  <td id="tableHTML_column_3">brexpiprazole dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A)</td>
  <td id="tableHTML_column_4">brexpiprazole is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is brexpiprazole dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A). The use of brexpiprazole in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">bright light therapy</td>
  <td id="tableHTML_column_3">bright light therapy also known as phototherapy, was originally used to treat patients with seasonal affective disorder and refers to the use of glare therapy to treat mood symptoms. The International Society of Bipolar Disorders (ISBD) Task Force on Chronobiology and Chronotherapy recommended BLT as the strongest evidence among current chronotherapeutic options in the acute treatment of bipolar depression.

Takeshima M, Utsumi T, Aoki Y, Wang Z, Suzuki M, Okajima I, Watanabe N, Watanabe K, Takaesu Y. Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2020; 74(4):247-256. doi: 10.1111/pcn.12976.

Wang S, Zhang Z, Yao L, Ding N, Jiang L, Wu Y. Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0232798. doi: 10.1371/journal.pone.0232798.

Gottlieb JF, Benedetti F, Geoffroy PA, Henriksen TEG, Lam RW, Murray G, Phelps J, Sit D, Swartz HA, Crowe M, Etain B, Frank E, Goel N, Haarman BCM, Inder M, Kallestad H, Jae Kim S, Martiny K, Meesters Y, Porter R, Riemersma-van der Lek RF, Ritter PS, Schulte PFJ, Scott J, Wu JC, Yu X, Chen S. The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. Bipolar Disord. 2019; 21(8):741-773. doi: 10.1111/bdi.12847.</td>
  <td id="tableHTML_column_4">bright light therapy is a <u>Biological non-pharmacological</u> intervention. <br>bright light therapy bright light therapy also known as phototherapy, was originally used to treat patients with seasonal affective disorder and refers to the use of glare therapy to treat mood symptoms. The International Society of Bipolar Disorders (ISBD) Task Force on Chronobiology and Chronotherapy recommended BLT as the strongest evidence among current chronotherapeutic options in the acute treatment of bipolar depression.

Takeshima M, Utsumi T, Aoki Y, Wang Z, Suzuki M, Okajima I, Watanabe N, Watanabe K, Takaesu Y. Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2020; 74(4):247-256. doi: 10.1111/pcn.12976.

Wang S, Zhang Z, Yao L, Ding N, Jiang L, Wu Y. Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0232798. doi: 10.1371/journal.pone.0232798.

Gottlieb JF, Benedetti F, Geoffroy PA, Henriksen TEG, Lam RW, Murray G, Phelps J, Sit D, Swartz HA, Crowe M, Etain B, Frank E, Goel N, Haarman BCM, Inder M, Kallestad H, Jae Kim S, Martiny K, Meesters Y, Porter R, Riemersma-van der Lek RF, Ritter PS, Schulte PFJ, Scott J, Wu JC, Yu X, Chen S. The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. Bipolar Disord. 2019; 21(8):741-773. doi: 10.1111/bdi.12847.. The use of bright light therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">bupropion</td>
  <td id="tableHTML_column_3">bupropion norepinephrine, dopamine inhibiteur recapture (NET, DAT), relâche (NE, DA)</td>
  <td id="tableHTML_column_4">bupropion is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is bupropion norepinephrine, dopamine inhibiteur recapture (NET, DAT), relâche (NE, DA). The use of bupropion in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">carbamazepine</td>
  <td id="tableHTML_column_3">carbamazepine glutamate voltage-gated sodium and calcium channel blocker</td>
  <td id="tableHTML_column_4">carbamazepine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is carbamazepine glutamate voltage-gated sodium and calcium channel blocker. <br><u>This intervention is indicated in</u> <ul><li> Acute manic and mixed episodes in bipolar I disorder with a recommeded dose of Initial dose: 200 mg orally twice a day, Increase by 200 mg per day to achieve optimal response with a recommeded dose of Initial dose: 200 mg orally twice a day, Increase by 200 mg per day to achieve optimal response up to a maximum dose of 1600 mg per day up to a maximum dose of 1600 mg per day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">carer focused intervention</td>
  <td id="tableHTML_column_3">carer focused intervention psychological interventions that aim to improve the experience of caregiving in bipolar disorder. Common components of these psychoeducational interventions include education about the nature of bipolar disorder, triggers and warning signs, treatment, management, and the impact on and role of caregivers. 

Baruch E, Pistrang N, Barker C. Psychological interventions for caregivers of people with bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2018; 236:187-198. doi: 10.1016/j.jad.2018.04.077.</td>
  <td id="tableHTML_column_4">carer focused intervention is a <u>Psychosocial</u> intervention. <br>carer focused intervention carer focused intervention psychological interventions that aim to improve the experience of caregiving in bipolar disorder. Common components of these psychoeducational interventions include education about the nature of bipolar disorder, triggers and warning signs, treatment, management, and the impact on and role of caregivers. 

Baruch E, Pistrang N, Barker C. Psychological interventions for caregivers of people with bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2018; 236:187-198. doi: 10.1016/j.jad.2018.04.077.. The use of carer focused intervention in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">cariprazine</td>
  <td id="tableHTML_column_3">cariprazine dopamine, serotonin receptor partial agonist (D3/2, 5-HT1A), receptor antagonist (5-HT2B)</td>
  <td id="tableHTML_column_4">cariprazine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is cariprazine dopamine, serotonin receptor partial agonist (D3/2, 5-HT1A), receptor antagonist (5-HT2B). <br><u>This intervention is indicated in</u> <ul><li> Manic or Mixed Episodes associated with Bipolar I Disorder with a recommeded dose of 3–6 mg once daily with a recommeded dose of 3–6 mg once daily up to a maximum dose of 6 mg daily up to a maximum dose of 6 mg daily </li><li> Depressive Episodes associated with Bipolar Disorder with a recommeded dose of 1.5 or 3 mg once daily with a recommeded dose of 1.5 or 3 mg once daily up to a maximum dose of 3 mg daily up to a maximum dose of 3 mg daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">CBT</td>
  <td id="tableHTML_column_3">CBT is usually given in an individual or group format and aims at modifying maladaptive thoughts through cognitive restructuring. CBT has also behavioral components including interpersonal skills training, behavioral activation, or scheduling pleasurable life events to provide social reinforcement, problem solving, and “third-wave” components such as mindfulness, acceptance, and commitment. Some CBT programs may have only elements of behavioral or third-wave therapies without cognitive restructuring. 

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993</td>
  <td id="tableHTML_column_4">CBT is a <u>Psychosocial</u> intervention. <br>CBT CBT is usually given in an individual or group format and aims at modifying maladaptive thoughts through cognitive restructuring. CBT has also behavioral components including interpersonal skills training, behavioral activation, or scheduling pleasurable life events to provide social reinforcement, problem solving, and “third-wave” components such as mindfulness, acceptance, and commitment. Some CBT programs may have only elements of behavioral or third-wave therapies without cognitive restructuring. 

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993. The use of CBT in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">celecoxib</td>
  <td id="tableHTML_column_3">celecoxib nonsteroidal anti-inflammatory drug (NSAID)</td>
  <td id="tableHTML_column_4">celecoxib is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is celecoxib nonsteroidal anti-inflammatory drug (NSAID). The use of celecoxib in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">chlorpromazine</td>
  <td id="tableHTML_column_3">chlorpromazine dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4">chlorpromazine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is chlorpromazine dopamine, serotonin receptor antagonist (D2, 5-HT2). The use of chlorpromazine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">choline</td>
  <td id="tableHTML_column_3">choline essential nutrient, precursor of acetylcholine and a methyl donor in various metabolic processes, and in lipid metabolism.</td>
  <td id="tableHTML_column_4">choline is a <u>Nutraceutical</u> intervention. <br>choline choline essential nutrient, precursor of acetylcholine and a methyl donor in various metabolic processes, and in lipid metabolism.. The use of choline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">citalopram</td>
  <td id="tableHTML_column_3">citalopram serotonin reuptake inhibition (SERT)</td>
  <td id="tableHTML_column_4">citalopram is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is citalopram serotonin reuptake inhibition (SERT). The use of citalopram in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">clonazepam</td>
  <td id="tableHTML_column_3">clonazepam GABA positive allosteric modulator, GABA-A receptor, benzodiazepine site</td>
  <td id="tableHTML_column_4">clonazepam is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is clonazepam GABA positive allosteric modulator, GABA-A receptor, benzodiazepine site. The use of clonazepam in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">coenzyme Q10</td>
  <td id="tableHTML_column_3">coenzyme Q10 antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation</td>
  <td id="tableHTML_column_4">coenzyme Q10 is a <u>Nutraceutical</u> intervention. <br>coenzyme Q10 coenzyme Q10 antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. The use of coenzyme Q10 in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">creatine</td>
  <td id="tableHTML_column_3">creatine essential, non-proteinaceous amino acid constituent of skeletal muscle tissue of vertebrates, and is obtained through the diet or is endogenously synthesized in the body</td>
  <td id="tableHTML_column_4">creatine is a <u>Nutraceutical</u> intervention. <br>creatine creatine essential, non-proteinaceous amino acid constituent of skeletal muscle tissue of vertebrates, and is obtained through the diet or is endogenously synthesized in the body. The use of creatine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">desipramine</td>
  <td id="tableHTML_column_3">desipramine norepinephrine reuptake inhibitor (NET)</td>
  <td id="tableHTML_column_4">desipramine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is desipramine norepinephrine reuptake inhibitor (NET). The use of desipramine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">dexamphetamine</td>
  <td id="tableHTML_column_3">dexamphetamine dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)</td>
  <td id="tableHTML_column_4">dexamphetamine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is dexamphetamine dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE). The use of dexamphetamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">dextromethorphan</td>
  <td id="tableHTML_column_3">dextromethorphan NMDA receptor antagonist</td>
  <td id="tableHTML_column_4">dextromethorphan is a <u>Nutraceutical</u> intervention. <br>dextromethorphan dextromethorphan NMDA receptor antagonist. The use of dextromethorphan in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">divalproate</td>
  <td id="tableHTML_column_3">divalproate anticonvulsant may act through multiple mechanisms. It may increase gamma-aminobutyric acid (GABA)-mediated neurotransmission, modulate voltage-gated sodium channels, affect signaling systems including Wnt/beta-catenin and ERK pathways, and interfere with inositol and arachidonate metabolism.</td>
  <td id="tableHTML_column_4">divalproate is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is divalproate anticonvulsant may act through multiple mechanisms. It may increase gamma-aminobutyric acid (GABA)-mediated neurotransmission, modulate voltage-gated sodium channels, affect signaling systems including Wnt/beta-catenin and ERK pathways, and interfere with inositol and arachidonate metabolism.. <br><u>This intervention is indicated in</u> <ul><li>  Acute management of mania associated with bipolar disorder with a recommeded dose of Initial dose is 750 mg daily increasing as rapidly as possible to achieve therapeutic response or desired plasma level. with a recommeded dose of Initial dose is 750 mg daily increasing as rapidly as possible to achieve therapeutic response or desired plasma level. up to a maximum dose of 60 mg/kg/day. up to a maximum dose of 60 mg/kg/day.</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">ECT</td>
  <td id="tableHTML_column_3">ECT a brain stimulation medical treatment used for severe mental health conditions, particularly when other treatments haven't worked well enough. During ECT, a small amount of electric current is passed through the brain, intentionally triggering a brief seizure. ECT devices are categorized as Class II devices for treating catatonia or severe major depressive episodes linked with major depressive disorder or bipolar disorder in patients aged 13 years and older who exhibit treatment resistance or necessitate a rapid response due to the severity of their psychiatric or medical condition.</td>
  <td id="tableHTML_column_4">ECT is a <u>Biological non-pharmacological</u> intervention. <br>ECT ECT a brain stimulation medical treatment used for severe mental health conditions, particularly when other treatments haven't worked well enough. During ECT, a small amount of electric current is passed through the brain, intentionally triggering a brief seizure. ECT devices are categorized as Class II devices for treating catatonia or severe major depressive episodes linked with major depressive disorder or bipolar disorder in patients aged 13 years and older who exhibit treatment resistance or necessitate a rapid response due to the severity of their psychiatric or medical condition.. The use of ECT in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">endoxifen</td>
  <td id="tableHTML_column_3">endoxifen a secondary tamoxifen metabolite, potent antiestrogen exhibiting estrogen receptor alpha (ERa) binding</td>
  <td id="tableHTML_column_4">endoxifen is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is endoxifen a secondary tamoxifen metabolite, potent antiestrogen exhibiting estrogen receptor alpha (ERa) binding. The use of endoxifen in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">erythropoietin</td>
  <td id="tableHTML_column_3">erythropoietin glycoprotein hormone which stimulates red blood cell formation</td>
  <td id="tableHTML_column_4">erythropoietin is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is erythropoietin glycoprotein hormone which stimulates red blood cell formation. The use of erythropoietin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">escitalopram</td>
  <td id="tableHTML_column_3">escitalopram serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4">escitalopram is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is escitalopram serotonin reuptake inhibitor (SERT). The use of escitalopram in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">esketamine</td>
  <td id="tableHTML_column_3">esketamine N-methyl-d-aspartate (NMDA) receptor antagonist and S-enantiomer of racemic ketamine</td>
  <td id="tableHTML_column_4">esketamine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is esketamine N-methyl-d-aspartate (NMDA) receptor antagonist and S-enantiomer of racemic ketamine. The use of esketamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">eslicarbazepine</td>
  <td id="tableHTML_column_3">eslicarbazepine anticonvulsant acting as voltage-gated sodium channel blocker</td>
  <td id="tableHTML_column_4">eslicarbazepine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is eslicarbazepine anticonvulsant acting as voltage-gated sodium channel blocker. The use of eslicarbazepine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">family focused therapy</td>
  <td id="tableHTML_column_3">family focused therapy is a psychosocial intervention for adults and children with bipolar disorder and their caregivers (parents, spouse, or extended relatives), usually given in conjunction with pharmacotherapy. Programs involve conjoint sessions of psychoeducation regarding bipolar disorder, communication enhancement training, and problem-solving skills training.

Miklowitz DJ, Chung B. Family-Focused Therapy for Bipolar Disorder: Reflections on 30 Years of Research. Fam Process. 2016; 55(3):483-99. doi: 10.1111/famp.12237.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">family focused therapy is a <u>Psychosocial</u> intervention. <br>family focused therapy family focused therapy is a psychosocial intervention for adults and children with bipolar disorder and their caregivers (parents, spouse, or extended relatives), usually given in conjunction with pharmacotherapy. Programs involve conjoint sessions of psychoeducation regarding bipolar disorder, communication enhancement training, and problem-solving skills training.

Miklowitz DJ, Chung B. Family-Focused Therapy for Bipolar Disorder: Reflections on 30 Years of Research. Fam Process. 2016; 55(3):483-99. doi: 10.1111/famp.12237.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of family focused therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">family/conjoint therapy</td>
  <td id="tableHTML_column_3">family/conjoint therapy have common elements including the involvement of the family, psychoeducation, and skills training. Family/conjoint therapy may be also labeled as family-focused psychoeducation, family-focused therapy, inpatient family intervention, behavioral family management, psychoeducational marital therapy, multifamily group psychoeducation, caregiver-focused psychoeducation, or conjoint psychoeducation. 

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">family/conjoint therapy is a <u>Psychosocial</u> intervention. <br>family/conjoint therapy family/conjoint therapy have common elements including the involvement of the family, psychoeducation, and skills training. Family/conjoint therapy may be also labeled as family-focused psychoeducation, family-focused therapy, inpatient family intervention, behavioral family management, psychoeducational marital therapy, multifamily group psychoeducation, caregiver-focused psychoeducation, or conjoint psychoeducation. 

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of family/conjoint therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">fluoxetine</td>
  <td id="tableHTML_column_3">fluoxetine serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4">fluoxetine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is fluoxetine serotonin reuptake inhibitor (SERT). <br><u>This intervention is indicated in</u> <ul><li> Depressive Episodes associated with Bipolar I Disorder in adults with a recommeded dose of Oral in combination with olanzapine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily with a recommeded dose of Oral in combination with olanzapine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily </li><li> Depressive Episodes associated with Bipolar I Disorder in children and adolescents with a recommeded dose of Oral in combination with olanzapine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily with a recommeded dose of Oral in combination with olanzapine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">folic acid</td>
  <td id="tableHTML_column_3">folic acid member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis</td>
  <td id="tableHTML_column_4">folic acid is a <u>Nutraceutical</u> intervention. <br>folic acid folic acid member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. The use of folic acid in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">functional remediation</td>
  <td id="tableHTML_column_3">functional remediation is an intervention that has been shown to improve outcomes in people with bipolar disorder by reducing global disability and improving interpersonal and occupational functioning. Unlike patient and family psychoeducation, cognitive behavioural therapy and interpersonal social rhythm therapy, it focuses on psychosocial adjustment rather than mood improvement or relapse prevention.  Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016 Oct;15(3):288-289. doi: 10.1002/wps.20351.</td>
  <td id="tableHTML_column_4">functional remediation is a <u>Psychosocial</u> intervention. <br>functional remediation functional remediation is an intervention that has been shown to improve outcomes in people with bipolar disorder by reducing global disability and improving interpersonal and occupational functioning. Unlike patient and family psychoeducation, cognitive behavioural therapy and interpersonal social rhythm therapy, it focuses on psychosocial adjustment rather than mood improvement or relapse prevention.  Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016 Oct;15(3):288-289. doi: 10.1002/wps.20351.. The use of functional remediation in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">gabapentin</td>
  <td id="tableHTML_column_3">gabapentin glutamate alpha-2 delta calcium channel blocker</td>
  <td id="tableHTML_column_4">gabapentin is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is gabapentin glutamate alpha-2 delta calcium channel blocker. The use of gabapentin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">galantamine</td>
  <td id="tableHTML_column_3">galantamine acetylcholine enzyme inhibitor (acetylcholinesterase), alpha -7 nicotinic receptor positive allosteric modulator</td>
  <td id="tableHTML_column_4">galantamine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is galantamine acetylcholine enzyme inhibitor (acetylcholinesterase), alpha -7 nicotinic receptor positive allosteric modulator. The use of galantamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">haloperidol</td>
  <td id="tableHTML_column_3">haloperidol dopamine receptor antagonist (D2)</td>
  <td id="tableHTML_column_4">haloperidol is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is haloperidol dopamine receptor antagonist (D2). The use of haloperidol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">idazoxan</td>
  <td id="tableHTML_column_3">idazoxan selective a2 adrenergic receptor antagonist</td>
  <td id="tableHTML_column_4">idazoxan is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is idazoxan selective a2 adrenergic receptor antagonist. The use of idazoxan in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">imipramine</td>
  <td id="tableHTML_column_3">imipramine serotonin, norepinephrine reuptake inhibitor (SERT and NET)</td>
  <td id="tableHTML_column_4">imipramine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is imipramine serotonin, norepinephrine reuptake inhibitor (SERT and NET). The use of imipramine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">infliximab</td>
  <td id="tableHTML_column_3">infliximab monoclonal antibody acting as tumor necrosis factor (TNF-a) blocker</td>
  <td id="tableHTML_column_4">infliximab is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is infliximab monoclonal antibody acting as tumor necrosis factor (TNF-a) blocker. The use of infliximab in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">inositol</td>
  <td id="tableHTML_column_3">inositol nutrient supplement working as second messenger in several cellular processes</td>
  <td id="tableHTML_column_4">inositol is a <u>Nutraceutical</u> intervention. <br>inositol inositol nutrient supplement working as second messenger in several cellular processes. The use of inositol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">insulin</td>
  <td id="tableHTML_column_3">insulin recombinant form of human insulin used to control hyperglycemia caused by Type 1 and Type 2 Diabetes</td>
  <td id="tableHTML_column_4">insulin is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is insulin recombinant form of human insulin used to control hyperglycemia caused by Type 1 and Type 2 Diabetes. The use of insulin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">Interpersonal and social rhythm therapy (IPSRT)</td>
  <td id="tableHTML_column_3">Interpersonal and social rhythm therapy (IPSRT) is an individual therapy with two components: interpersonal problem solving and social rhythm regularization, such as maintaining regular sleep/wake and other daily routines. 

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">Interpersonal and social rhythm therapy (IPSRT) is a <u>Psychosocial</u> intervention. <br>Interpersonal and social rhythm therapy (IPSRT) Interpersonal and social rhythm therapy (IPSRT) is an individual therapy with two components: interpersonal problem solving and social rhythm regularization, such as maintaining regular sleep/wake and other daily routines. 

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of Interpersonal and social rhythm therapy (IPSRT) in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">ketamine</td>
  <td id="tableHTML_column_3">ketamine glutamate NMDA antagonist</td>
  <td id="tableHTML_column_4">ketamine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is ketamine glutamate NMDA antagonist. The use of ketamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">l-sulpride</td>
  <td id="tableHTML_column_3">l-sulpride prokinetic agent and peripheral dopamine D2 receptor antagonist</td>
  <td id="tableHTML_column_4">l-sulpride is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is l-sulpride prokinetic agent and peripheral dopamine D2 receptor antagonist. The use of l-sulpride in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lamotrigine</td>
  <td id="tableHTML_column_3">lamotrigine glutamate voltage-gated sodium channel blocker</td>
  <td id="tableHTML_column_4">lamotrigine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is lamotrigine glutamate voltage-gated sodium channel blocker. <br><u>This intervention is indicated in</u> <ul><li> Bipolar Disorder in patients =18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy with a recommeded dose of 200 mg/day with a recommeded dose of 200 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">levetiracetam</td>
  <td id="tableHTML_column_3">levetiracetam antiepileptic drug acting as a modulator of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain</td>
  <td id="tableHTML_column_4">levetiracetam is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is levetiracetam antiepileptic drug acting as a modulator of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain. The use of levetiracetam in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">licarbazepine</td>
  <td id="tableHTML_column_3">licarbazepine antiepileptic drug acting as voltage-gated sodium channels inhibitor</td>
  <td id="tableHTML_column_4">licarbazepine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is licarbazepine antiepileptic drug acting as voltage-gated sodium channels inhibitor. The use of licarbazepine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lisdexamfetamine</td>
  <td id="tableHTML_column_3">lisdexamfetamine dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)</td>
  <td id="tableHTML_column_4">lisdexamfetamine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is lisdexamfetamine dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE). The use of lisdexamfetamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lithium</td>
  <td id="tableHTML_column_3">lithium lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 3</td>
  <td id="tableHTML_column_4">lithium is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is lithium lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 3. <br><u>This intervention is indicated in</u> <ul><li> Treatment of acute manic and mixed episodes in patients 7 years and older with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L </li><li> Maintenance Treatment for Bipolar I Disorder (patients 7 years and older) with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lithium</td>
  <td id="tableHTML_column_3">lithium lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 4</td>
  <td id="tableHTML_column_4">lithium is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is lithium lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 4. <br><u>This intervention is indicated in</u> <ul><li> Treatment of acute manic and mixed episodes in patients 7 years and older with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L </li><li> Maintenance Treatment for Bipolar I Disorder (patients 7 years and older) with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lumateperone</td>
  <td id="tableHTML_column_3">lumateperone serotonin 5-HT2A receptor antagonist, a dopamine D2 receptor presynaptic partial agonist and postsynaptic antagonist, a D1 receptor–dependent modulator of glutamate, and a serotonin reuptake inhibitor.</td>
  <td id="tableHTML_column_4">lumateperone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is lumateperone serotonin 5-HT2A receptor antagonist, a dopamine D2 receptor presynaptic partial agonist and postsynaptic antagonist, a D1 receptor–dependent modulator of glutamate, and a serotonin reuptake inhibitor.. <br><u>This intervention is indicated in</u> <ul><li> Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. with a recommeded dose of 42 mg administered orally once daily with a recommeded dose of 42 mg administered orally once daily up to a maximum dose of 42 mg/day up to a maximum dose of 42 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lurasidone</td>
  <td id="tableHTML_column_3">lurasidone dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4">lurasidone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is lurasidone dopamine, serotonin receptor antagonist (D2, 5-HT2). <br><u>This intervention is indicated in</u> <ul><li> Depressive episodes associated with Bipolar I Disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate with a recommeded dose of 20 mg to 120 mg per day with a recommeded dose of 20 mg to 120 mg per day up to a maximum dose of 120 mg per day up to a maximum dose of 120 mg per day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">melatonin</td>
  <td id="tableHTML_column_3">melatonin melatonin receptor agonist (Mel1 and Mel2)</td>
  <td id="tableHTML_column_4">melatonin is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is melatonin melatonin receptor agonist (Mel1 and Mel2). The use of melatonin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">memantine</td>
  <td id="tableHTML_column_3">memantine glutamate receptor antagonist (NMDA)</td>
  <td id="tableHTML_column_4">memantine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is memantine glutamate receptor antagonist (NMDA). The use of memantine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">minocycline</td>
  <td id="tableHTML_column_3">minocycline tetracycline antibiotic with pleiotropic antineuroinflammatory properties</td>
  <td id="tableHTML_column_4">minocycline is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is minocycline tetracycline antibiotic with pleiotropic antineuroinflammatory properties. The use of minocycline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">moclobemide</td>
  <td id="tableHTML_column_3">moclobemide serotonin, norepinephrine, dopamine reversible enzyme inhibitor (MAO-A)</td>
  <td id="tableHTML_column_4">moclobemide is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is moclobemide serotonin, norepinephrine, dopamine reversible enzyme inhibitor (MAO-A). The use of moclobemide in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">modafinil</td>
  <td id="tableHTML_column_3">modafinil dopamine reuptake inhibitor (DAT)</td>
  <td id="tableHTML_column_4">modafinil is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is modafinil dopamine reuptake inhibitor (DAT). The use of modafinil in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">n-acetyl cysteine</td>
  <td id="tableHTML_column_3">n-acetyl cysteine pharmacological antioxidant and cytoprotectant acting as a reductant of disulfide bonds, a scavenger of reactive oxygen species and/or a precursor for glutathione biosynthesis</td>
  <td id="tableHTML_column_4">n-acetyl cysteine is a <u>Nutraceutical</u> intervention. <br>n-acetyl cysteine n-acetyl cysteine pharmacological antioxidant and cytoprotectant acting as a reductant of disulfide bonds, a scavenger of reactive oxygen species and/or a precursor for glutathione biosynthesis. The use of n-acetyl cysteine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">naltrexone</td>
  <td id="tableHTML_column_3">naltrexone opioid receptor antagonist (µ,<U+03BA>)</td>
  <td id="tableHTML_column_4">naltrexone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is naltrexone opioid receptor antagonist (µ,<U+03BA>). The use of naltrexone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">olanzapine</td>
  <td id="tableHTML_column_3">olanzapine dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4">olanzapine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is olanzapine dopamine, serotonin receptor antagonist (D2, 5-HT2). <br><u>This intervention is indicated in</u> <ul><li> Bipolar I Disorder (manic or mixed episodes) in adults with a recommeded dose of 5 mg to 20 mg/day with a recommeded dose of 5 mg to 20 mg/day up to a maximum dose of 20 mg/day up to a maximum dose of 20 mg/day </li><li> Bipolar I Disorder (manic or mixed episodes) in adolescents with a recommeded dose of 2.5 to 20 mg/day with a recommeded dose of 2.5 to 20 mg/day up to a maximum dose of 20 mg/day up to a maximum dose of 20 mg/day </li><li> Agitation associated with Bipolar I Mania in adults with a recommeded dose of IM: 10 mg (5 mg or 7.5 mg when clinically warranted) with a recommeded dose of IM: 10 mg (5 mg or 7.5 mg when clinically warranted)</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">omega3</td>
  <td id="tableHTML_column_3">omega3 polyunsaturated fatty acids mediate anti-inflammatory effects by suppressing lipogenic gene expression, increasing fatty acid beta-oxidation, increasing lipo-protein-lipase (LPL) expression, and influencing total body lipid accumulation.</td>
  <td id="tableHTML_column_4">omega3 is a <u>Nutraceutical</u> intervention. <br>omega3 omega3 polyunsaturated fatty acids mediate anti-inflammatory effects by suppressing lipogenic gene expression, increasing fatty acid beta-oxidation, increasing lipo-protein-lipase (LPL) expression, and influencing total body lipid accumulation.. The use of omega3 in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">oxcarbazepine</td>
  <td id="tableHTML_column_3">oxcarbazepine glutamate voltage-gated sodium and calcium channel blocker</td>
  <td id="tableHTML_column_4">oxcarbazepine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is oxcarbazepine glutamate voltage-gated sodium and calcium channel blocker. The use of oxcarbazepine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">paliperidone</td>
  <td id="tableHTML_column_3">paliperidone dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2)</td>
  <td id="tableHTML_column_4">paliperidone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is paliperidone dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2). <br><u>This intervention is indicated in</u> <ul><li> Schizoaffective disorder ­ adults with a recommeded dose of 3 - 12 mg/day with a recommeded dose of 3 - 12 mg/day up to a maximum dose of 12 mg/day up to a maximum dose of 12 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">paroxetine</td>
  <td id="tableHTML_column_3">paroxetine serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4">paroxetine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is paroxetine serotonin reuptake inhibitor (SERT). The use of paroxetine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">phenelzine</td>
  <td id="tableHTML_column_3">phenelzine serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B)</td>
  <td id="tableHTML_column_4">phenelzine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is phenelzine serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B). The use of phenelzine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pindolol</td>
  <td id="tableHTML_column_3">pindolol beta adrenoceptor antagonist</td>
  <td id="tableHTML_column_4">pindolol is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is pindolol beta adrenoceptor antagonist. The use of pindolol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pioglitazone</td>
  <td id="tableHTML_column_3">pioglitazone thiazolidinediones act as synthetic ligands for peroxisome proliferator-activated receptors (PPARs). Pioglitazone improves glycaemic control by improving insulin sensitivity through its action on PPAR gamma 1 and PPAR gamma 2 and by affecting lipid metabolism through its action on PPAR alpha.</td>
  <td id="tableHTML_column_4">pioglitazone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is pioglitazone thiazolidinediones act as synthetic ligands for peroxisome proliferator-activated receptors (PPARs). Pioglitazone improves glycaemic control by improving insulin sensitivity through its action on PPAR gamma 1 and PPAR gamma 2 and by affecting lipid metabolism through its action on PPAR alpha.. The use of pioglitazone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">placebo</td>
  <td id="tableHTML_column_3">placebo a therapeutic effect, drug or non-drug, or part thereof, which objectively has no specific pharmacodynamic action in the condition being treated.</td>
  <td id="tableHTML_column_4">placebo is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is placebo a therapeutic effect, drug or non-drug, or part thereof, which objectively has no specific pharmacodynamic action in the condition being treated.. The use of placebo in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pramipexole</td>
  <td id="tableHTML_column_3">pramipexole dopamine receptor agonist (D2)</td>
  <td id="tableHTML_column_4">pramipexole is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is pramipexole dopamine receptor agonist (D2). The use of pramipexole in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pregnenolone</td>
  <td id="tableHTML_column_3">pregnenolone precursor to gonadal steroid hormones and the adrenal corticosteroids</td>
  <td id="tableHTML_column_4">pregnenolone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is pregnenolone precursor to gonadal steroid hormones and the adrenal corticosteroids. The use of pregnenolone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation</td>
  <td id="tableHTML_column_3">psychoeducation an intervention that consists of six or more sessions in which patients, and sometimes family members, are given information about disease characteristics, the importance of adherence to treatment, early recognition of prodromal signs of relapse/recurrence, management of mood symptoms or comorbid conditions, and lifestyle regularity.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">psychoeducation is a <u>Psychosocial</u> intervention. <br>psychoeducation psychoeducation an intervention that consists of six or more sessions in which patients, and sometimes family members, are given information about disease characteristics, the importance of adherence to treatment, early recognition of prodromal signs of relapse/recurrence, management of mood symptoms or comorbid conditions, and lifestyle regularity.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of psychoeducation in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation brief  </td>
  <td id="tableHTML_column_3">psychoeducation brief   is a brief form of psychoeducation consisting of fewer than 3 psychoeducation sessions delivered in a group, family, or individual format. Such interventions sometimes include skills training tasks for patients with bipolar disorder, such as regulating sleep-wake cycles or monitoring prodromal symptoms. A self-guided workbook is often included.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">psychoeducation brief   is a <u>Psychosocial</u> intervention. <br>psychoeducation brief   psychoeducation brief   is a brief form of psychoeducation consisting of fewer than 3 psychoeducation sessions delivered in a group, family, or individual format. Such interventions sometimes include skills training tasks for patients with bipolar disorder, such as regulating sleep-wake cycles or monitoring prodromal symptoms. A self-guided workbook is often included.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of psychoeducation brief   in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation group</td>
  <td id="tableHTML_column_3">psychoeducation group is a psychoeducational program provided in a group format.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">psychoeducation group is a <u>Psychosocial</u> intervention. <br>psychoeducation group psychoeducation group is a psychoeducational program provided in a group format.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of psychoeducation group in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation individual</td>
  <td id="tableHTML_column_3">psychoeducation individual is a psychoeducational program provided in an individual format.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">psychoeducation individual is a <u>Psychosocial</u> intervention. <br>psychoeducation individual psychoeducation individual is a psychoeducational program provided in an individual format.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of psychoeducation individual in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">quetiapine</td>
  <td id="tableHTML_column_3">quetiapine dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2) and reuptake inhibitor (NET)</td>
  <td id="tableHTML_column_4">quetiapine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is quetiapine dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2) and reuptake inhibitor (NET). <br><u>This intervention is indicated in</u> <ul><li> Bipolar Mania- Adults Monotherapy with a recommeded dose of 400– 800 mg/day with a recommeded dose of 400– 800 mg/day up to a maximum dose of 800 mg/day up to a maximum dose of 800 mg/day </li><li> Bipolar Mania- Children and Adolescents (10 to 17 years), Monotherapy with a recommeded dose of 400–600 mg/day with a recommeded dose of 400–600 mg/day up to a maximum dose of 600 mg/day up to a maximum dose of 600 mg/day </li><li> Bipolar Depression- Adults with a recommeded dose of 300 mg/day with a recommeded dose of 300 mg/day up to a maximum dose of 300 mg/day up to a maximum dose of 300 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">ramelteon</td>
  <td id="tableHTML_column_3">ramelteon melatonin receptor agonist (Mel1 and Mel2)</td>
  <td id="tableHTML_column_4">ramelteon is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is ramelteon melatonin receptor agonist (Mel1 and Mel2). The use of ramelteon in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">riluzole</td>
  <td id="tableHTML_column_3">riluzole glutamate antagonist</td>
  <td id="tableHTML_column_4">riluzole is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is riluzole glutamate antagonist. The use of riluzole in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">risperidone</td>
  <td id="tableHTML_column_3">risperidone dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2)</td>
  <td id="tableHTML_column_4">risperidone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is risperidone dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2). <br><u>This intervention is indicated in</u> <ul><li> Bipolar mania – adults with a recommeded dose of 1-6 mg/day with a recommeded dose of 1-6 mg/day up to a maximum dose of 6 mg/day up to a maximum dose of 6 mg/day </li><li> Bipolar mania in children/ adolescents with a recommeded dose of 0.5-6 mg/day with a recommeded dose of 0.5-6 mg/day up to a maximum dose of 6 mg/day up to a maximum dose of 6 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">rTMS</td>
  <td id="tableHTML_column_3">rTMS is a non-invasive brain stimulation technique that uses electromagnetic pulses delivered by a powerful and focused electromagnetic coil to induce electrical currents in neural tissue, modulating neuronal activity in targeted brain regions.</td>
  <td id="tableHTML_column_4">rTMS is a <u>Biological non-pharmacological</u> intervention. <br>rTMS rTMS is a non-invasive brain stimulation technique that uses electromagnetic pulses delivered by a powerful and focused electromagnetic coil to induce electrical currents in neural tissue, modulating neuronal activity in targeted brain regions.. The use of rTMS in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">sAME</td>
  <td id="tableHTML_column_3">sAME it affects the regulation of a wide range of critical components of neurotransmission and is involved in three central metabolic pathways including trans-sulfuration, transaminopropylation, and methylation</td>
  <td id="tableHTML_column_4">sAME is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is sAME it affects the regulation of a wide range of critical components of neurotransmission and is involved in three central metabolic pathways including trans-sulfuration, transaminopropylation, and methylation. The use of sAME in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">selegiline</td>
  <td id="tableHTML_column_3">selegiline dopamine, norepinephrine, serotonin enzyme inhibitor (MAO-B and -A)</td>
  <td id="tableHTML_column_4">selegiline is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is selegiline dopamine, norepinephrine, serotonin enzyme inhibitor (MAO-B and -A). The use of selegiline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">sertraline</td>
  <td id="tableHTML_column_3">sertraline serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4">sertraline is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is sertraline serotonin reuptake inhibitor (SERT). The use of sertraline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">sham</td>
  <td id="tableHTML_column_3">sham is a control procedure or intervention that is similar to, but omits a key therapeutic element of the treatment or procedure under investigation</td>
  <td id="tableHTML_column_4">sham is a <u>Biological non-pharmacological</u> intervention. <br>sham sham is a control procedure or intervention that is similar to, but omits a key therapeutic element of the treatment or procedure under investigation. The use of sham in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">supportive therapy</td>
  <td id="tableHTML_column_3">supportive therapy Supportive therapy is an unstructured therapy without specific psychological techniques other than those common to all approaches and may be delivered in an individual or group format. It is based on the assumption that the therapeutic alliance is the crucial element of therapy and that relief from personal problems can be achieved through discussion with others.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4">supportive therapy is a <u>Psychosocial</u> intervention. <br>supportive therapy supportive therapy Supportive therapy is an unstructured therapy without specific psychological techniques other than those common to all approaches and may be delivered in an individual or group format. It is based on the assumption that the therapeutic alliance is the crucial element of therapy and that relief from personal problems can be achieved through discussion with others.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. The use of supportive therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">t3 hormone</td>
  <td id="tableHTML_column_3">t3 hormone Exogenous triiodothyronine exerts the effects of the endogenous thyroid T3 hormone</td>
  <td id="tableHTML_column_4">t3 hormone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is t3 hormone Exogenous triiodothyronine exerts the effects of the endogenous thyroid T3 hormone. The use of t3 hormone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">t4 hormone</td>
  <td id="tableHTML_column_3">t4 hormone Exogenous T4 hormone refers to synthetic or supplemental thyroxine, which is a form of thyroid hormone</td>
  <td id="tableHTML_column_4">t4 hormone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is t4 hormone Exogenous T4 hormone refers to synthetic or supplemental thyroxine, which is a form of thyroid hormone. The use of t4 hormone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">tamoxifen</td>
  <td id="tableHTML_column_3">tamoxifen selective estrogen receptor modulator</td>
  <td id="tableHTML_column_4">tamoxifen is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is tamoxifen selective estrogen receptor modulator. The use of tamoxifen in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">TAU</td>
  <td id="tableHTML_column_3">TAU treatment as usual</td>
  <td id="tableHTML_column_4">TAU is a <u>Psychosocial</u> intervention. <br>TAU TAU treatment as usual. The use of TAU in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">tDCS</td>
  <td id="tableHTML_column_3">tDCS is a non-invasive neuromodulation technique that delivers a well-tolerated electrical current to the brain through scalp electrodes.</td>
  <td id="tableHTML_column_4">tDCS is a <u>Biological non-pharmacological</u> intervention. <br>tDCS tDCS is a non-invasive neuromodulation technique that delivers a well-tolerated electrical current to the brain through scalp electrodes.. The use of tDCS in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">topiramate</td>
  <td id="tableHTML_column_3">topiramate GABA, glutamate facilitation of GABA transmission, receptor antagonist on AMPA and KA</td>
  <td id="tableHTML_column_4">topiramate is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is topiramate GABA, glutamate facilitation of GABA transmission, receptor antagonist on AMPA and KA. The use of topiramate in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">total sleep deprivation</td>
  <td id="tableHTML_column_3">total sleep deprivation involves being deprived of total sleep for approximately 36 hours straight, from daytime until next day’s evening. Treatment usually consists in one to six cycles.

Ramirez-Mahaluf JP, Rozas-Serri E, Ivanovic-Zuvic F, Risco L, Vöhringer PA. Effectiveness of Sleep Deprivation in Treating Acute Bipolar Depression as Augmentation Strategy: A Systematic Review and Meta-Analysis. Front Psychiatry. 2020 Feb 25;11:70. doi: 10.3389/fpsyt.2020.00070.</td>
  <td id="tableHTML_column_4">total sleep deprivation is a <u>Biological non-pharmacological</u> intervention. <br>total sleep deprivation total sleep deprivation involves being deprived of total sleep for approximately 36 hours straight, from daytime until next day’s evening. Treatment usually consists in one to six cycles.

Ramirez-Mahaluf JP, Rozas-Serri E, Ivanovic-Zuvic F, Risco L, Vöhringer PA. Effectiveness of Sleep Deprivation in Treating Acute Bipolar Depression as Augmentation Strategy: A Systematic Review and Meta-Analysis. Front Psychiatry. 2020 Feb 25;11:70. doi: 10.3389/fpsyt.2020.00070.. The use of total sleep deprivation in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">tranylcypromine</td>
  <td id="tableHTML_column_3">tranylcypromine serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B), releaser (DA, NE)</td>
  <td id="tableHTML_column_4">tranylcypromine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is tranylcypromine serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B), releaser (DA, NE). The use of tranylcypromine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">valnoctamide</td>
  <td id="tableHTML_column_3">valnoctamide a central nervous system active chiral constitutional isomer of valpromide, the corresponding amide of valproic acid, which exhibits stereoselective pharmacokinetics in humans and animals.</td>
  <td id="tableHTML_column_4">valnoctamide is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is valnoctamide a central nervous system active chiral constitutional isomer of valpromide, the corresponding amide of valproic acid, which exhibits stereoselective pharmacokinetics in humans and animals.. The use of valnoctamide in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">venlafaxine</td>
  <td id="tableHTML_column_3">venlafaxine serotonin, norepinephrine reuptake inhibitor (SERT and NET)</td>
  <td id="tableHTML_column_4">venlafaxine is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is venlafaxine serotonin, norepinephrine reuptake inhibitor (SERT and NET). The use of venlafaxine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">verapamil</td>
  <td id="tableHTML_column_3">verapamil non-dihydropyridine calcium channel blocker</td>
  <td id="tableHTML_column_4">verapamil is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is verapamil non-dihydropyridine calcium channel blocker. The use of verapamil in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">vitD3</td>
  <td id="tableHTML_column_3">vitD3 exogenous vitamine D3 is commonly used to supplement dietary intake and ensure adequate levels of vitamin D</td>
  <td id="tableHTML_column_4">vitD3 is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is vitD3 exogenous vitamine D3 is commonly used to supplement dietary intake and ensure adequate levels of vitamin D. The use of vitD3 in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">withania somnifer</td>
  <td id="tableHTML_column_3">withania somnifer is a medicinal herb reported to have antioxidant, anti-inflammatory, and immunomodulatory properties</td>
  <td id="tableHTML_column_4">withania somnifer is a <u>Nutraceutical</u> intervention. <br>withania somnifer withania somnifer is a medicinal herb reported to have antioxidant, anti-inflammatory, and immunomodulatory properties. The use of withania somnifer in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">ziprasidone</td>
  <td id="tableHTML_column_3">ziprasidone dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4">ziprasidone is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is ziprasidone dopamine, serotonin receptor antagonist (D2, 5-HT2). <br><u>This intervention is indicated in</u> <ul><li> Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder with a recommeded dose of 40-80 mg twice daily with a recommeded dose of 40-80 mg twice daily </li><li> Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate with a recommeded dose of 40-80 mg twice daily with a recommeded dose of 40-80 mg twice daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">zonisamide</td>
  <td id="tableHTML_column_3">zonisamide sulfonamide anticonvulsant may act by blocking repetitive firing of voltage-sensitive sodium channels and reducing voltage-sensitive T-type calcium currents</td>
  <td id="tableHTML_column_4">zonisamide is a <u>Pharmacological</u> intervention. <br> Its mechanism of action is zonisamide sulfonamide anticonvulsant may act by blocking repetitive firing of voltage-sensitive sodium channels and reducing voltage-sensitive T-type calcium currents. The use of zonisamide in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
</tbody>
</table>
